Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

CaDAnCe-302, a phase 3, open-label, randomized study of BGB-16673 compared with idelalisib + rituximab (R), bendamustine + R, or venetoclax + R re-treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma previously exposed to both a BTK and BCL2 inhibitor

View Full Paper
Ask AI
Bookmark
Share

Authors

JSJohn F. SeymourMYMaryam Sarraf YazdyPBPatrick A. Brown

Discussion

Loading...

Member takes

Overview

Phase 3 trial compares BGB-16673 with idelalisib + rituximab or venetoclax + rituximab in CLL/SLL patients, suggesting BGB-16673 may improve progression-free survival.

Key Points

  • Evaluate the efficacy and safety of BGB-16673 in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
  • Phase 3, open-label, randomized trial across 101 sites in 14 countries
  • Patients ≥18 with CLL/SLL relapsed after BTK and BCL2 inhibitors
  • Primary endpoint: progression-free survival assessed by independent review committee.
  • BGB-16673 compared with idelalisib + rituximab or venetoclax + rituximab in patients with CLL/SLL
  • Expected improvements in progression-free survival and response rates
  • Focus on safety and tolerability through National Cancer Institute criteria.

Cite This Study

Seymour et al. (2025) studied this question.

synapsesocial.com/papers/69362f7d4fa91c937236e4f9https://doi.org/10.1182/blood-2025-8245
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1CaDAnCe-304, a phase 3, open-label, randomized study to evaluate the safety and efficacy of Bruton tyrosine kinase degrader BGB-16673 compared with pirtobrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma2025 · 1 citations
  2. 2CaDAnCe-104, an ongoing, open-label, phase 1b/2 master protocol study of Bruton tyrosine kinase degrader BGB-16673 in combination with other agents in patients with relapsed/refractory B-cell malignancies2025 · 3 citations
  3. 3Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory Richter transformation: Results from the ongoing phase 1 CaDAnCe-101 study2025 · 1 citations
  4. 4Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory indolent non-Hodgkin lymphoma from the ongoing phase 1 CaDAnCe-101 study2025
  5. 5Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory Waldenström macroglobulinemia from the ongoing phase 1 CaDAnCe-101 study2025 · 4 citations